Immunosppressive Agents in Inflammatory Bowel Disease: Current Status and Future Prospects
Inflammatory bowel disease involves an interaction between genetic susceptibility factors and environmental triggers, and the intestinal injury is mediated by the host immunoinflammatory response. Identification of the mechanisms and mediators that contribute to the tissue injury has provided a soun...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1994-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1994/580410 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399538609029120 |
|---|---|
| author | Fergus Shanahan Gerald C O'’Sullivan J Kevin Collins |
| author_facet | Fergus Shanahan Gerald C O'’Sullivan J Kevin Collins |
| author_sort | Fergus Shanahan |
| collection | DOAJ |
| description | Inflammatory bowel disease involves an interaction between genetic susceptibility factors and environmental triggers, and the intestinal injury is mediated by the host immunoinflammatory response. Identification of the mechanisms and mediators that contribute to the tissue injury has provided a sound rationale for the therapeutic use of immunosuppressive and immunomodulatory agents. The efficacy of traditional immunosuppressive drugs, such as the purine analogues in both Crohn’s disease and ulcerative colitis, is well established. The major limitation of the use of these drugs is the delayed clinical response associated with their use. This has prompted an evaluation of other immunosuppressivcs, such as cyclosporine and related drugs, that have a more rapid onset of action. Convincing data indicate a distinct role for cyclosporine in certain patients with acute severe ulcerative colitis. However, despite early promising results with cyclosporine in Crohn’s disease, recent results have been less encouraging. There is also uncertainty about the exact clinical role of cyclosporine because of concerns regarding long term toxicity. At present, many investigators regard cyclosporine as an interim measure for acutely ill patients. The challenge that remains is the development of novel immunomodulatory strategies that are specific for the mucosal immune system and that are based on recent advances in our understanding of the pathogenesis of mucosal inflammation. |
| format | Article |
| id | doaj-art-a2eefaa9dd5d437182a704bafd4c8a02 |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 1994-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-a2eefaa9dd5d437182a704bafd4c8a022025-08-20T03:38:18ZengWileyCanadian Journal of Gastroenterology0835-79001994-01-018638338710.1155/1994/580410Immunosppressive Agents in Inflammatory Bowel Disease: Current Status and Future ProspectsFergus Shanahan0Gerald C O'’Sullivan1J Kevin Collins2Department of Medicine, Clinical and Molecular Research Group, University College Cork, Cork, IrelandDepartment of Medicine, Clinical and Molecular Research Group, University College Cork, Cork, IrelandDepartment of Medicine, Clinical and Molecular Research Group, University College Cork, Cork, IrelandInflammatory bowel disease involves an interaction between genetic susceptibility factors and environmental triggers, and the intestinal injury is mediated by the host immunoinflammatory response. Identification of the mechanisms and mediators that contribute to the tissue injury has provided a sound rationale for the therapeutic use of immunosuppressive and immunomodulatory agents. The efficacy of traditional immunosuppressive drugs, such as the purine analogues in both Crohn’s disease and ulcerative colitis, is well established. The major limitation of the use of these drugs is the delayed clinical response associated with their use. This has prompted an evaluation of other immunosuppressivcs, such as cyclosporine and related drugs, that have a more rapid onset of action. Convincing data indicate a distinct role for cyclosporine in certain patients with acute severe ulcerative colitis. However, despite early promising results with cyclosporine in Crohn’s disease, recent results have been less encouraging. There is also uncertainty about the exact clinical role of cyclosporine because of concerns regarding long term toxicity. At present, many investigators regard cyclosporine as an interim measure for acutely ill patients. The challenge that remains is the development of novel immunomodulatory strategies that are specific for the mucosal immune system and that are based on recent advances in our understanding of the pathogenesis of mucosal inflammation.http://dx.doi.org/10.1155/1994/580410 |
| spellingShingle | Fergus Shanahan Gerald C O'’Sullivan J Kevin Collins Immunosppressive Agents in Inflammatory Bowel Disease: Current Status and Future Prospects Canadian Journal of Gastroenterology |
| title | Immunosppressive Agents in Inflammatory Bowel Disease: Current Status and Future Prospects |
| title_full | Immunosppressive Agents in Inflammatory Bowel Disease: Current Status and Future Prospects |
| title_fullStr | Immunosppressive Agents in Inflammatory Bowel Disease: Current Status and Future Prospects |
| title_full_unstemmed | Immunosppressive Agents in Inflammatory Bowel Disease: Current Status and Future Prospects |
| title_short | Immunosppressive Agents in Inflammatory Bowel Disease: Current Status and Future Prospects |
| title_sort | immunosppressive agents in inflammatory bowel disease current status and future prospects |
| url | http://dx.doi.org/10.1155/1994/580410 |
| work_keys_str_mv | AT fergusshanahan immunosppressiveagentsininflammatoryboweldiseasecurrentstatusandfutureprospects AT geraldcosullivan immunosppressiveagentsininflammatoryboweldiseasecurrentstatusandfutureprospects AT jkevincollins immunosppressiveagentsininflammatoryboweldiseasecurrentstatusandfutureprospects |